{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:53:08Z","timestamp":1771480388247,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmech.2023.115863","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:14:42Z","timestamp":1696677282000},"page":"115863","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of quinoline-piperazine\/pyrrolidine derivatives as possible antileishmanial agents"],"prefix":"10.1016","volume":"261","author":[{"given":"Sarita","family":"Katiyar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol Chhatrapati","family":"Bisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garvita","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin Nashik","family":"Sanap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabi Sankar","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bidyut","family":"Purkait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neena","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8339-568X","authenticated-orcid":false,"given":"Koneni V.","family":"Sashidhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115863_bib1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.115863_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/qjmed\/hct116","article-title":"Leishmaniasis: clinical syndromes and treatment","volume":"107","author":"McGwire","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.ejmech.2023.115863_bib3","series-title":"WHO. Leishmaniasis","year":"2023"},{"key":"10.1016\/j.ejmech.2023.115863_bib4","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1021\/acs.jmedchem.3c00056","article-title":"Optimization of orally bioavailable antileishmanial 2,4,5-trisubstituted benzamides","volume":"66","author":"Kim","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib5","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1021\/cr400552x","article-title":"Fruitful decade for antileishmanial compounds from 2002 to late 2011","volume":"114","author":"Hussain","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2023.115863_bib6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/microorganisms8071069","article-title":"Can we harness immune responses to improve drug treatment in leishmaniasis","volume":"8","author":"Aruleba","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.ejmech.2023.115863_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006052","article-title":"Drug resistance and treatment failure in leishmaniasis: a 21st century challenge","volume":"11","author":"Ponte-Sucre","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2023.115863_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1128\/AAC.01415-06","article-title":"Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes","volume":"51","author":"Luque-Ortega","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115863_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115863_bib10","first-page":"16","article-title":"Sodium stibogluconate: therapeutic use in the Management of Leishmaniasis","volume":"45","author":"Roychoudhury","year":"2008","journal-title":"Indian J. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2023.115863_bib11","first-page":"69","article-title":"Review of the current treatments for leishmaniases","volume":"3","author":"Lindoso","year":"2012","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.ejmech.2023.115863_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejmech.2018.08.012","article-title":"An update on small molecule strategies targeting leishmaniasis","volume":"157","author":"Kapil","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11030-019-09953-4","article-title":"Insights into the current status of privileged N-heterocycles as antileishmanial agents","volume":"24","author":"Razzaghi-Asl","year":"2020","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2023.115863_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113865","article-title":"Recent contributions of quinolines to antimalarial and anticancer drug discovery research","volume":"226","author":"Van de Walle","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11030-019-09953-4","article-title":"Insights into the current status of privileged N-heterocycles as antileishmanial agents","volume":"24","author":"Razzaghi-Asl","year":"2020","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2023.115863_bib16","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.bmc.2014.12.018","article-title":"Quinoline-based antimalarial hybrid compounds","volume":"23","author":"Vandekerckhove","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/17460441.2017.1319357","article-title":"An overview of quinoline as a privileged scaffold in cancer drug discovery","volume":"12","author":"Musiol","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115863_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/med.21262","article-title":"Antituberculosis drug research: a critical overview","volume":"33","author":"Beena","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2023.115863_bib19","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2174\/092986710791163966","article-title":"Quinoline-based antifungals","volume":"17","author":"Musiol","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.22270\/jddt.v9i4-s.3414","article-title":"Quinoline as TRPV1 antagonists: a new approach against inflammation","volume":"9","author":"Ambatkar","year":"2019","journal-title":"J. Drug Deliv. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115863_bib21","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2174\/1389557518666181018163448","article-title":"A review on quinoline derived scaffolds as anti-HIV agents","volume":"19","author":"Chokkar","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib22","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1128\/AAC.49.12.4950-4956.2005","article-title":"Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases","volume":"49","author":"Nakayama","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115863_bib23","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ejmech.2016.08.049","article-title":"Antileishmanial ferrocenylquinoline derivatives: synthesis and biological evaluation against Leishmania donovani","volume":"124","author":"Yousuf","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib24","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1128\/AAC.00790-10","article-title":"Tafenoquine, an antiplasmodial 8-aminoquinoline, targets leishmania respiratory complex III and induces apoptosis","volume":"54","author":"Carvalho","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2023.115863_bib25","first-page":"1446","article-title":"Sitamaquine (GlaxoSmithKline\/Walter reed army institute)","volume":"3","author":"Yeates","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.115863_bib26","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/acs.jmedchem.9b00628","article-title":"Synthesis, biological evaluation, structure-activity relationship, and mechanism of action studies of quinoline-metronidazole derivatives against experimental visceral leishmaniasis","volume":"62","author":"Upadhyay","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2015.07.026","article-title":"Piperazine scaffold: a remarkable tool in generation of diverse pharmacological agents","volume":"102","author":"Shaquiquzzaman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib28","doi-asserted-by":"crossref","first-page":"38328","DOI":"10.1039\/D0RA07881F","article-title":"Synthesis, study of antileishmanial and antitrypanosomal activity of imidazo pyridine fused triazole analogues","volume":"10","author":"Nandikolla","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.115863_bib29","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.ejmech.2008.03.039","article-title":"Nitroimidazolyl-1,3,4-thiadiazole-based anti-leishmanial agents: synthesis and in vitro biological evaluation","volume":"44","author":"Poorrajab","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113516","article-title":"Design, synthesis, in vitro and in vivo biological evaluation of pyranone-piperazine analogs as potent antileishmanial agents","volume":"221","author":"Mishra","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/14756366.2021.1969385","article-title":"Pyrrolidine-based 3-deoxysphingosylphosphorylcholine analogs as possible candidates against neglected tropical diseases (NTDs): identification of hit compounds towards development of potential treatment of Leishmania donovani","volume":"36","author":"Hassan","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1590\/S0102-695X2013005000022","article-title":"Antileishmanial activity of amides from Piper amalago and synthetic analogs","volume":"23","author":"da Silva Carrara","year":"2013","journal-title":"Rev. bras. Farmacogn."},{"key":"10.1016\/j.ejmech.2023.115863_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001625","article-title":"Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs","volume":"6","author":"Bell","year":"2012","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2023.115863_bib34","doi-asserted-by":"crossref","first-page":"9824","DOI":"10.1039\/C5NJ02010G","article-title":"Friedl\u00e4nder annulation: scope and limitations of metal salt Lewis acid catalysts in selectivity control for the synthesis of functionalised quinolines","volume":"39","author":"Tanwar","year":"2015","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1134\/S1070428009070161","article-title":"New syntheses on the basis of 4-hydroxy-2 H -chromen-2-ones","volume":"45","author":"Avetisyan","year":"2009","journal-title":"Russ. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib36","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.02.043","article-title":"Synthesis and biological evaluation of 4-oxycoumarin derivatives as a new class of antifilarial agents","volume":"94","author":"Misra","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib37","first-page":"439","article-title":"Exploration of antileishmanial activity in heterocycles; results of their in vivo & in vitro bioevaluations","volume":"89","author":"Bhatnagar","year":"1989","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ejmech.2023.115863_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd4683","article-title":"Hit and lead criteria in drug discovery for infectious diseases of the developing world","volume":"14","author":"Katsuno","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115863_bib39","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1128\/AAC.49.9.3776-3783.2005","article-title":"Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening, antimicrob","volume":"49","author":"Ashutosh","year":"2005","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2023.115863_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2023.115863_bib41","series-title":"Probit Analysis","author":"Finney","year":"1971"},{"key":"10.1016\/j.ejmech.2023.115863_bib42","first-page":"17","article-title":"Visceral leishmaniasis","author":"Kumar","year":"2021","journal-title":"Therapeut. Vaccines Dev. Immunol."},{"key":"10.1016\/j.ejmech.2023.115863_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2018.05.014","article-title":"Synthesis and evaluation of novel triazolyl quinoline derivatives as potential antileishmanial agents","volume":"154","author":"Upadhyay","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib44","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1039\/D2MD00464J","article-title":"Antileishmanial evaluation of triazole\u2013butenolide conjugates: design, synthesis, in vitro screening, SAR and in silico ADME predictions","volume":"14","author":"Pandey","year":"2023","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115863_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115340","article-title":"Design, synthesis and evaluation of novel pyrrole-hydroxybutenolide hybrids as promising antiplasmodial and anti-inflammatory agents","volume":"254","author":"Pandey","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423008309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:03:13Z","timestamp":1759330993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423008309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":45,"alternative-id":["S0223523423008309"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115863","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of quinoline-piperazine\/pyrrolidine derivatives as possible antileishmanial agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115863"}}